The North America Infectious Disease Diagnostics Market is poised for sustained growth driven by increasing investments in healthcare infrastructure, technological innovations, and a rise in infectious disease prevalence. With a market valuation of USD 6,830 Million in 2025, the market is expected to attain USD 15,340 Million by 2035, reflecting a CAGR of 8.1% during 2024-2035.
The economic impact of tariffs on "North America Infectious Disease Diagnostics Market".
Market Growth Drivers
Rising Prevalence of Infectious Diseases: The surge in infectious diseases such as COVID-19, influenza, and emerging pathogens across North America is significantly driving the demand for advanced diagnostic solutions. Companies like Bio-Rad Laboratories and Abbott have emphasized rapid development and deployment of molecular and immunological diagnostic technologies to facilitate early detection, control transmission, and monitor outbreaks. This has led to increased adoption of point-of-care testing and laboratory-based solutions, particularly in high-burden areas and among vulnerable populations, ensuring timely intervention and supporting public health strategies.
Technological Advancements in Diagnostic Platforms: Technological breakthroughs such as multiplex PCR, next-generation sequencing (NGS), and AI-powered diagnostic platforms are transforming the infectious disease diagnostics ecosystem. Companies like Thermo Fisher Scientific and Becton, Dickinson and Company are investing in research and partnerships to enhance the accuracy and speed of diagnostics. These developments have enabled healthcare providers to achieve faster turnaround times, improved sensitivity, and specificity, ultimately leading to better patient outcomes and more efficient disease control.
Market Trends
Increased Adoption of Point-of-Care Testing: The trend toward decentralized healthcare and patient-centric approaches has led to a surge in the usage of point-of-care (POC) diagnostic devices. Companies like Roche Diagnostics are launching innovative POC assays that deliver rapid and precise results at clinics, pharmacies, and even patient homes. This trend is revolutionizing infectious disease management by reducing diagnostic delays, optimizing resource allocation, and enabling prompt initiation of treatment, especially during acute outbreaks.
Expansion of Molecular Diagnostic Capabilities: Expanding molecular testing capabilities, such as real-time PCR and multiplex assays, continues to be a defining trend. Companies like Hologic Inc. are enhancing test menus to cover a broader array of pathogens and offering high-throughput solutions that cater to both hospital and reference laboratories. The expansion of direct-to-consumer diagnostic kits and collaborative ventures with telehealth providers is further propelling the shift toward proactive infectious disease screening and surveillance.
Market Opportunities
Personalized Medicine and Biomarker Discoveries: The increasing integration of genomics and personalized medicine in infectious disease diagnostics opens up avenues for tailoring therapies and monitoring disease progression. Companies investing in biomarker research, such as Quest Diagnostics, are at the forefront of this opportunity, offering tests that inform patient-specific treatment strategies.
Expansion into Untapped Rural Markets: Significant investments are being directed toward expanding access to diagnostics in underserved and rural regions. Companies collaborating with public health organizations to deploy mobile laboratories and self-testing solutions are positioned to capture a larger market segment while contributing to improved healthcare equity.
North America Infectious Disease Diagnostics Market Revenue (USD Million), 2020-2035
The revenue chart illustrates a robust growth trajectory for the North America Infectious Disease Diagnostics Market from USD 3,950 Million in 2020 to an anticipated USD 15,340 Million by 2035. This upward trend reflects the compounding impact of ongoing technological innovations, increasing disease incidence, and healthcare investment across the region. Steady year-over-year growth is projected, with critical inflection points attributed to advances in rapid molecular diagnostics, heightened public health awareness, and large-scale health crises such as the COVID-19 pandemic. The market's sustained expansion underscores the critical role of diagnostics in disease prevention, control, and surveillance.
North America Infectious Disease Diagnostics Market by Regions Share (%), 2025
In 2025, the United States dominates the North American Infectious Disease Diagnostics Market, accounting for 76% of the total market share, driven by major investments in diagnostic innovation and widespread implementation in healthcare settings. Canada holds a 17% share, reflecting robust healthcare policies and increased infectious disease testing. Mexico captures a 5% market share, with gradual growth due to improving healthcare infrastructure and cross-border collaborations. The remaining 2% is attributed to the rest of North America, including smaller territories and island regions, indicating potential areas for market expansion.
Recent Developments
In May 2024, Abbott announced the U.S. FDA approval of its Alinity m Resp-4-Plex assay, a multiplex molecular diagnostic that simultaneously detects and differentiates four major respiratory pathogens, including SARS-CoV-2, influenza A/B, and RSV. The launch enables hospitals and laboratories to streamline respiratory infection workflows, enhance diagnostic efficiency, and better respond to seasonal and pandemic surges.
In June 2024, Roche Diagnostics introduced the cobas Liat SARS-CoV-2 & Flu A/B molecular point-of-care test across North America. The launch addresses high demand for rapid, accurate, and scalable diagnostic solutions at ambulatory clinics, emergency departments, and pharmacies, underscoring Roche's commitment to innovative pandemic preparedness and response infrastructure.
In April 2024, Thermo Fisher Scientific entered a partnership with the US Centers for Disease Control and Prevention (CDC) to expand the deployment of next-generation sequencing (NGS) technology for tracking and surveillance of emerging infectious disease threats. This initiative supports public health readiness, enhances variant detection, and fosters data-driven strategies to mitigate regional outbreaks.
Press Releases